Abstract
Abstract We herein report two case of fatal congestive heart failure during osimertinib treatment for epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC). Case1: A 66-year-old woman presented with progressive palpitation and dyspnea two months after starting osimertinib for the treatment of EGFR T790M-positive NSCLC. An echocardiogram demonstrated severe decreased left ventricular systolic function. She was diagnosed with fatal congestive heart failure caused by osimertinib treatment. Her general condition deteriorated, and she died three months after starting osimertinib. Case2: A 84-year-old woman was treated for recurrent EGFR mutant NSCLC after lobectomy, and osimertinib was administered. Severe exertional dyspnea appeared one month after starting osimertinib. She was also diagnosed with fatal congestive heart failure caused by osimertinib, and died for a few days. The causal relationship between osimertinib and cardiotoxicity has so far received little attention and thus remains unclear. Osimertinib inhibits HER2 (ERBB2) in addition to EGFR (ERBB1), thereby potentially causing cardiotoxicity.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
